Succinate Dehydrogenase in Lung Cancer: from Molecular Mechanisms to Clinical Implications.
- 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
- 2Division of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Abstract
Lung cancer remains the malignancy with the highest global incidence and mortality rates, and its five-year survival rate is still unsatisfactory. Traditional treatment approaches face severe challenges from tumor heterogeneity and therapeutic resistance. Succinate dehydrogenase (SDH) is a key metabolic enzyme within mitochondria that participates in both the tricarboxylic acid (TCA) cycle and the electron transport chain. Through its unique tetrameric structure, it catalyzes the oxidation of succinate to fumarate and transfers electrons to ubiquinone, playing a central role in cellular energy metabolism. Recent studies indicate that SDH dysfunction can stabilize hypoxia-inducible factor-1α (HIF-1α) via the pseudohypoxia pathway, thereby inducing metabolic reprogramming, which is a mechanism implicated in the pathogenesis and progression of various cancers. This review systematically summarizes the molecular structural features and biological functions of SDH, along with its mechanisms of action in lung cancer initiation, progression, metastasis, and therapy resistance. Furthermore, it analyzes recent advances in potential diagnostic biomarkers and therapeutic targets based on SDH-mediated metabolic characteristics, with emphasis on the dual role of SDH5 in suppressing epithelial-mesenchymal transition (EMT) and promoting radiotherapy resistance, aiming to provide a theoretical foundation for a deeper understanding of lung cancer metabolism and the development of novel therapeutic strategies.
Related
- Dynamic Urothelial Remodeling in Diabetic Bladder Dysfunction: Disease-Course Changes, Molecular Mechanisms, and Clinical Implications
- DNA Damage in Diabetes: From Molecular Mechanisms to Clinical Implications
- Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma.
- Disconnect Between Succinate, Succinyl-CoA, and Histone Succinylation in Cells and Gastrointestinal Stromal Tumors with Succinate Dehydrogenase Deficiency
- Selective Serotonin Reuptake Inhibitor-Associated Bruxism: Neuropharmacologic Mechanisms and Clinical Implications
BibTeX
@article{du2026succinate,
title = {{Succinate Dehydrogenase in Lung Cancer: from Molecular Mechanisms to Clinical Implications.}},
author = {Yali Du and Lulu He and Yi Guo and Yuchen Zhang and Jianping He},
journal = {OncoTargets and therapy},
year = {2026},
month = oct,
doi = {10.2147/ott.s629223},
url = {https://europepmc.org/article/MED/42968940},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Succinate Dehydrogenase in Lung Cancer: from Molecular Mechanisms to Clinical Implications.
AU - Yali Du
AU - Lulu He
AU - Yi Guo
AU - Yuchen Zhang
AU - Jianping He
PY - 2026
DA - 2026/10/28
JO - OncoTargets and therapy
DO - 10.2147/ott.s629223
UR - https://europepmc.org/article/MED/42968940
AB - Lung cancer remains the malignancy with the highest global incidence and mortality rates, and its five-year survival rate is still unsatisfactory. Traditional treatment approaches face severe challenges from tumor heterogeneity and therapeutic resistance. Succinate dehydrogenase (SDH) is a key metabolic enzyme within mitochondria that participates in both the tricarboxylic acid (TCA) cycle and the electron transport chain. Through its unique tetrameric structure, it catalyzes the oxidation of succinate to fumarate and transfers electrons to ubiquinone, playing a central role in cellular energy metabolism. Recent studies indicate that SDH dysfunction can stabilize hypoxia-inducible factor-1α (HIF-1α) via the pseudohypoxia pathway, thereby inducing metabolic reprogramming, which is a mechanism implicated in the pathogenesis and progression of various cancers. This review systematically summarizes the molecular structural features and biological functions of SDH, along with its mechanisms of action in lung cancer initiation, progression, metastasis, and therapy resistance. Furthermore, it analyzes recent advances in potential diagnostic biomarkers and therapeutic targets based on SDH-mediated metabolic characteristics, with emphasis on the dual role of SDH5 in suppressing epithelial-mesenchymal transition (EMT) and promoting radiotherapy resistance, aiming to provide a theoretical foundation for a deeper understanding of lung cancer metabolism and the development of novel therapeutic strategies.
SN - 1178-6930
ER -